Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells.

Gils Roex Diana Campillo-Davo Donovan Flumens Philip Anthony Gilbert Shaw Laurens Krekelbergh Hans De Reu Zwi N Berneman Eva Lion Sébastien Anguille

Published in: Journal of translational medicine (2022)

Here, using the clinically validated NK-92 cell line as a therapeutic cell source, we established a readily accessible and flexible platform for the generation of highly functional dual-targeted CAR-NK cells.

Keyphrases

nk cells
cancer therapy
single cell
high throughput
stem cells